Relevant Professional Experience:

  • Social science reviewer for nearly 15 years in Division of Nonprescription Drugs

  • Reviewed hundreds of industry meeting packages representing a wide variety of therapeutic categories for Rx-OTC switch

  • Presented at eight public FDA Advisory Committee meetings

  • Analysis and guidance was Integral to approvals of Opill and Narcan

  • Social scientist of record in earlier approvals of Oxytrol, Nasacort, Differin, and Sklice

  • Social science lead on innovative FDA-sponsored label comprehension study for naloxone drugs; results published in May 27, 2020 issue of the New England Journal of Medicine; recipient of 2019 FDA Behavioral and Social Science Research Award for this initiative

  • In early 1990s, led marketing research group at Lederle Pharmaceuticals, supporting launch of ProStep nicotine patch for smoking cessation

Education:

  • MPA, Princeton University School of Public and International Affairs

  • BA, magna cum laude, University of Rochester